Australia Markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.36-0.22 (-1.90%)
At close: 04:00PM EST
11.38 +0.02 (+0.18%)
After hours: 05:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 339.12
52-week low 311.36
50-day moving average 316.15
200-day moving average 322.39

Share statistics

Avg vol (3-month) 31.46M
Avg vol (10-day) 32.34M
Shares outstanding 5142.52M
Implied shares outstanding 6N/A
Float 874.97M
% held by insiders 134.64%
% held by institutions 162.92%
Shares short (14 Dec 2021) 45.62M
Short ratio (14 Dec 2021) 44.5
Short % of float (14 Dec 2021) 46.43%
Short % of shares outstanding (14 Dec 2021) 43.95%
Shares short (prior month 14 Nov 2021) 45.67M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 0.00%
Operating margin (ttm)-653.68%

Management effectiveness

Return on assets (ttm)-13.65%
Return on equity (ttm)-24.01%

Income statement

Revenue (ttm)38.44M
Revenue per share (ttm)0.29
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -243.2M
Net income avi to common (ttm)-250.71M
Diluted EPS (ttm)-1.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)483.48M
Total cash per share (mrq)3.39
Total debt (mrq)53.87M
Total debt/equity (mrq)5.55
Current ratio (mrq)9.40
Book value per share (mrq)6.81

Cash flow statement

Operating cash flow (ttm)-149.35M
Levered free cash flow (ttm)-115.2M